Adacel vaccine contraindications and precautions (Please see Sanofi Pasteur product insert for complete list):
-
- Moderate or severe acute illness (with or without fever) until the illness resolves;
- Serious allergic or hypersensitivity reaction to a previous shot;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within seven days of a previous pertussis vaccination not attributable to another identifiable cause;
- In adolescents, a progressive neurologic disorder, including progressive encephalopathy or uncontrolled epilepsy (convulsions);
- In adults, an unstable neurologic condition, such as cerebrovascular events and acute encephalopathic conditions;
- If Guillain-Barré Syndrome (GBS) occurred within six weeks of a previous tetanus toxoid vaccine, the decision to administer Adacel should carefully examine the possible risk and benefits of Adacel prior to vaccination;
- Anyone who has experienced an Arthus-type hypersensitivity reaction following a previous dose of a tetanus toxoid vaccine should not receive Adacel more frequently than every 10 years;
- The tip caps of prefilled Adacel syringes contain latex and may cause an allergic reaction in persons sensitive to latex.
Adacel is approved to be administered in persons between the ages of 10 and 64 years of age. A second dose of Adacel may be administered if there has been an interval of at least eight years between a prior Tdap vaccine dose. Adacel should not be administered to children younger than 10 years or adults older than 64 years.
